CATALOGO DEI PRODOTTI DELLA RICERCA

ORSOLINI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.099
EU - Europa 4.267
AS - Asia 3.080
SA - Sud America 436
Continente sconosciuto - Info sul continente non disponibili 201
AF - Africa 85
OC - Oceania 9
Totale 13.177
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.904
RU - Federazione Russa 1.774
SG - Singapore 1.194
CN - Cina 947
GB - Regno Unito 662
IT - Italia 588
BR - Brasile 326
DE - Germania 287
VN - Vietnam 252
HK - Hong Kong 221
SE - Svezia 218
FR - Francia 215
IE - Irlanda 192
CA - Canada 106
FI - Finlandia 104
KR - Corea 91
IN - India 89
BD - Bangladesh 68
JP - Giappone 57
UA - Ucraina 39
NL - Olanda 37
AR - Argentina 35
PL - Polonia 35
MX - Messico 29
ES - Italia 28
ZA - Sudafrica 26
AT - Austria 25
TR - Turchia 21
BE - Belgio 20
ID - Indonesia 20
VE - Venezuela 18
CO - Colombia 17
IQ - Iraq 17
NG - Nigeria 15
CL - Cile 13
PH - Filippine 11
EC - Ecuador 10
UZ - Uzbekistan 10
CW - ???statistics.table.value.countryCode.CW??? 9
PY - Paraguay 9
TG - Togo 9
GT - Guatemala 8
IR - Iran 8
NI - Nicaragua 8
PK - Pakistan 8
PR - Porto Rico 8
AZ - Azerbaigian 7
IL - Israele 7
MA - Marocco 7
MY - Malesia 7
AU - Australia 6
CR - Costa Rica 6
JM - Giamaica 6
SV - El Salvador 6
TT - Trinidad e Tobago 6
BJ - Benin 5
CZ - Repubblica Ceca 5
GR - Grecia 5
JO - Giordania 5
RO - Romania 5
SA - Arabia Saudita 5
AE - Emirati Arabi Uniti 4
AM - Armenia 4
EG - Egitto 4
HN - Honduras 4
KE - Kenya 4
LB - Libano 4
NP - Nepal 4
SC - Seychelles 4
DK - Danimarca 3
KG - Kirghizistan 3
LT - Lituania 3
AL - Albania 2
BO - Bolivia 2
CY - Cipro 2
DZ - Algeria 2
EE - Estonia 2
KW - Kuwait 2
LA - Repubblica Popolare Democratica del Laos 2
MK - Macedonia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PA - Panama 2
PE - Perù 2
PS - Palestinian Territory 2
RS - Serbia 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
UY - Uruguay 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BS - Bahamas 1
BW - Botswana 1
CD - Congo 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CM - Camerun 1
Totale 12.962
Salva come PNG Salva come JPEG
Città #
Ashburn 670
Singapore 649
Moscow 630
Southend 555
San Jose 507
Chandler 478
Dallas 461
Hong Kong 216
Dublin 190
Council Bluffs 167
Beijing 162
New York 139
Jacksonville 136
Verona 135
Redmond 134
The Dalles 115
Los Angeles 101
Ann Arbor 94
Ho Chi Minh City 83
Bologna 74
Lawrence 70
Princeton 70
Wilmington 68
Woodbridge 66
Helsinki 59
Hanoi 56
Shenyang 55
Munich 53
Tokyo 53
Jinan 50
Santa Clara 49
Milan 45
Nanjing 45
Denver 42
Houston 41
Buffalo 39
São Paulo 38
Redondo Beach 37
Tianjin 35
Hebei 34
Montreal 30
Sindelfingen 30
Orem 28
Zhengzhou 27
Warsaw 26
Brooklyn 25
Haikou 25
Hangzhou 25
Ningbo 25
Changsha 23
Chicago 23
Columbus 23
Phoenix 23
Guangzhou 22
London 22
Seattle 22
Taiyuan 21
Washington 21
Atlanta 20
Brussels 19
Hyderabad 19
Rome 18
Vienna 18
Boston 17
Frankfurt am Main 17
San Francisco 17
Falkenstein 16
Johannesburg 16
Poplar 16
Abuja 15
Nanchang 15
Taizhou 15
Turku 15
Manchester 14
Norwalk 14
Redwood City 14
Toronto 14
Jiaxing 13
Amsterdam 12
Venice 12
Charlotte 11
Chennai 11
Dong Ket 11
Fuzhou 11
Rio de Janeiro 11
Fairfield 10
Mexico City 10
Mumbai 10
Tashkent 10
Calgary 9
Da Nang 9
Lomé 9
Naples 9
North Bergen 9
Seoul 9
Willemstad 9
Boardman 8
Jakarta 8
Palermo 8
Paris 8
Totale 7.678
Salva come PNG Salva come JPEG
Nome #
Artrite Reumatoide e Metabolismo Minerale 295
Bone Metabolism in a Large Cohort of Patients with Systemic Sclerosis 257
Anti-CCP antibodies and bone 255
Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women 243
Hajdu Cheney Syndrome; report of a novel NOTCH2 mutation and treatment with denosumab 227
Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis 224
Amino-Bisphosphonates and Cardiovascular Risk: A New Hypothesis Involving the Effects on Gamma-Delta T Cells 221
Bone involvement and osteoporosis in mastocytosis. 217
Clinical profile and outcome of patients with rheumatoid arthritis and abnormally high aortic stiffness 214
Concentric left ventricular remodelling is associated with subclinical systolic dysfunction in patients with psoriatic arthritis 211
Parathyroid hormone is a determinant of serum Dickkopf-1 levels in ankylosing spondylitis 210
A Multidisciplinary Diagnostic Approach Reveals a Higher Prevalence of Indolent Systemic Mastocytosis: 15-Years’ Experience of the GISM Network 202
Effects of TNF Inhibitors on Parathyroid Hormone and Wnt Signaling Antagonists in Rheumatoid Arthritis 193
Correction to: Is the exposure to bisphosphonates or osteoporosis the predictor of spinal radiographic progression in ankylosing spondylitis? 190
An exploratory study on the role of vitamin D supplementation in improving pain and disease activity in rheumatoid arthritis 190
Osteoporosis treatment: why ibandronic acid? 187
Denosumab for the Treatment of Mastocytosis-Related Osteoporosis: A Case Series 186
Bone Disease in Mastocytosis 185
BIOMARKERS LABORATORISTICI RELATIVI AL COINVOLGIMENTO OSSEO NELLE ARTROPATIE INFIAMMATORIE 185
Effects of biological and targeted synthetic DMARDs on bone loss in rheumatoid arthritis 185
Cancer in adult patients with inflammatory arthritis is associated with high ascending aortic stiffness and left ventricular hypertrophy and diastolic dysfunction 185
Association between long-term exposure to air pollution and immune-mediated diseases: a population-based cohort study 185
Association between environmental air pollution and rheumatoid arthritis flares 184
In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density 181
Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases 176
Bone health, an often forgotten comorbidity in systemic lupus erythematosus: a comment on the new recommendations 175
Relationship between common carotid distensibility/aortic stiffness and cardiac left ventricular morphology and function in a group of patients affected by chronic rheumatic diseases: an observational study 173
Osteoporosis: an Independent Determinant of Bone Erosions in Rheumatoid Arthritis? 169
Clinical profile and outcome of patients with chronic inflammatory arthritis and metabolic syndrome 169
Effects of antiangiogenetic drugs on microcirculation and macrocirculation in patients with advanced-stage renal cancer 168
Long-term Effects of Neridronate in Adults with Osteogenesis Imperfecta: An Observational Three-Year Italian Study 166
Cardiovascular morbidity and mortality in patients with rheumatic disease: hyperuricemia, a forgotten puzzle piece? 166
Is the exposure to bisphosphonates or osteoporosis the predictor of spinal radiographic progression in ankylosing spondylitis? 164
Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros 160
Disease Activity and Anticitrullinated Peptide Antibody Positivity Predict the Worsening of Ventricular Function in Rheumatoid Arthritis 160
Higher body mass index is associated with a lower iloprost infusion rate tolerance and higher iloprost-related adverse events in patients with systemic sclerosis 157
Regional differences of vitamin D deficiency in rheumatoid arthritis patients in Italy. 157
Inhibition of tumor necrosis factor-alpha (TNF-alpha) in patients with early rheumatoid arthritis results in acute changes of bone modulators 156
Changes in bone turnover markers and bone modulators during abatacept treatment 155
Underlying systemic mastocytosis in patients with unexplained osteoporosis: score proposal 155
Real-life short-term effectiveness of anti-osteoporotic treatments: a longitudinal cohort study 152
Short-Term Effects of TNF Inhibitors on Bone Turnover Markers and Bone Mineral Density in Rheumatoid Arthritis 151
Environmental Air Pollution Is a Predictor of Poor Response to Biological Drugs in Chronic Inflammatory Arthritides 151
Rheumatoid arthritis, γδ T cells and bisphosphonates 150
Osteoporosis in Inflammatory Arthritides: New Perspective on Pathogenesis and Treatment 150
High prevalence of occult heart disease in normotensive patients with rheumatoid arthritis 148
Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase 148
Sex-Specific Association of Left Ventricular Hypertrophy With Rheumatoid Arthritis 146
Association between exposure to fine particulate matter and osteoporosis: a population-based cohort study 145
Factors associated with accelerated subclinical atherosclerosis in patients with spondyloarthritis without overt cardiovascular disease 144
Titer-Dependent Effect of Anti-Citrullinated Protein Antibodies On Systemic Bone Mass in Rheumatoid Arthritis Patients 143
Osteoporosis in Rheumatic Diseases 143
Predictors and prognostic role of low myocardial mechano-energetic efficiency in chronic inflammatory arthritis 139
Zoledronic Acid in Osteoporosis Secondary to Mastocytosis. 138
The Emerging Roles of Endocrine Hormones in Different Arthritic Disorders 136
Traditional cardiovascular risk factors and residual disease activity are associated with atherosclerosis progression in rheumatoid arthritis patients 134
Immunoglobulin G4-Related Disease Responder Index Correlates With the Risk of 1-Year Relapse in Type 1 Autoimmune Pancreatitis 132
Left ventricular hypertrophy predicts poorer cardiovascular outcome in normotensive normoglycemic patients with rheumatoid arthritis 132
Traditional cardiovascular risk factors or inflammation: Which factors accelerate atherosclerosis in arthritis patients? 129
Ultrasonographic non-radiographic erosions could predict the efficacy of belimumab in articular systemic lupus erythematosus 128
Vitamin D serum levels and the risk of digital ulcers in systemic sclerosis: A longitudinal study 126
Incidence and predictors of adverse clinical events in patients with rheumatoid arthritis and asymptomatic left ventricular systolic dysfunction 125
Clinical image: ultrasound findings and magnetic resonance imaging comparison in the muscular involvement in polyarteritis nodosa 124
Vitamin D and disease severity in coronavirus disease 19 (COVID-19) 123
Usefulness of CHA2 DS2 -VASc score to predict mortality and hospitalization in patients with inflammatory arthritis 122
Risk of fragility fractures in obesity and diabetes: a retrospective analysis on a nation-wide cohort 121
Tumour necrosis factor inhibitors reduce aortic stiffness progression in patients with long-standing rheumatoid arthritis 120
The troubling liaison between cancer and metabolic syndrome in chronic inflammatory rheumatic diseases 119
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort 114
Incidence and predictors of new onset left ventricular diastolic dysfunction in asymptomatic patients with rheumatoid arthritis without overt cardiac disease 110
Could Previous Exposure to Nitrogen-Containing Bisphosphonates Mitigate Friendly Fire? 107
Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis? 104
The role of 18FDG-PET imaging in VEXAS syndrome: a multicentric case series and a systematic review of the literature 103
Effects of tofacitinib on bone turnover markers and bone modulators in patients with rheumatoid arthritis 102
Lack of Effect of Teriparatide on Joint Erosions in Rheumatoid Arthritis Is an Expected Result: Comment on the Article by Solomon et al 102
Different fracture risk profile in patients treated with anti-osteoporotic drugs in real-life 100
Effectiveness of influenza vaccine in TNF inhibitors treated patients: comment on the article by Burmester et al 99
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting 96
Reply to "Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis in remission: What is the right dose?" 95
New insights on the role, pathogenesis, and treatment of osteoporosis and bone erosions in rheumatoid arthritis 94
Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies 87
Prevalence and determinants of vertebral fractures in a SLE cohort 84
Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement 83
Subclinical Myocardial Fibrosis in Systemic Lupus Erythematosus as Assessed by Pulse-Cancellation Echocardiography: A Pilot Study 82
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study-Joint and Skin (BeRLiSS-JS) 77
Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group 51
Parvovirus B19 infection with rheumatologic manifestations: results from a multicentre Italian study 17
Fracture risk tools performance and potential use in systemic lupus erythematosus 13
Totale 13.177
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.178
article - articoli 47.659
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 519
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 96.356
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022330 0 0 0 0 23 8 19 27 58 10 40 145
2022/20231.332 83 147 105 246 120 311 18 66 167 11 46 12
2023/2024757 32 60 70 90 77 146 30 40 13 26 134 39
2024/20251.710 82 103 77 285 90 50 76 68 265 152 140 322
2025/20265.736 368 286 376 973 1.530 390 535 306 403 262 155 152
2026/20271.047 60 139 189 542 117 0 0 0 0 0 0 0
Totale 13.177